Human LIGHT, His Tag (LIT-H5247) is expressed from human 293 cells (HEK293). It contains AA Asp 74 - Val 240 (Accession # O43557-1).
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 20.9 kDa. The protein migrates as 24-26 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS with Arginine, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human LIGHT, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human HVEM, Fc Tag (Cat. No. HVM-H5258) at 2 μg/mL (100 μL/well) can bind Human LIGHT, His Tag (Cat. No. LIT-H5247) with a linear range of 1-16 ng/mL (QC tested).
Loaded Human DcR3, Fc Tag (Cat. No. TNB-H5255) on AHC Biosensor, can bind Human LIGHT, His Tag (Cat. No. LIT-H5247) with an affinity constant of 4.94 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Tumor necrosis factor ligand superfamily member 14(LIGHT) is a tumor necrosis factor (TNF) superfamily ligand that regulates T cell immune responses by signaling through the herpes virus entry mediator (HVEM) and the lymphotoxin beta receptor (LTbetaR). LIGHT has emerged as a potent initiator of T cell co-stimulation signals effecting CTL-mediated tumor rejection, allograft rejection and graft versus host disease. Constitutive expression of LIGHT leads to tissue destruction and autoimmune-like disease syndromes.